Tirosint FDA Approval History: From NDA to Current Labeling

Tirosint is the brand name for levothyroxine sodium (synthetic T4) supplied as a soft gelatin capsule rather than a compressed tablet. It is manufactured by IBSA Institut Biochimique SA and is distinct from Tirosint-SOL, an oral liquid solution of the same active ingredient approved separately. Both are prescription thyroid hormone replacement products in the same pharmacologic class as tablet levothyroxine products such as Synthroid and generic levothyroxine.

The FDA approved the original Tirosint capsule under NDA 021924. This article covers what that approval covered, what has changed in the label since, and what the available evidence does and does not show about whether the gel capsule behaves differently in the body than a tablet.

Direct answer: Tirosint (levothyroxine sodium gel capsule, NDA 021924) received FDA approval as a new formulation of an already-established active ingredient, not as a novel drug, and its approved indications (hypothyroidism replacement and TSH suppression in thyroid cancer) are identical to those of tablet levothyroxine products. The gel capsule's main documented difference is its excipient profile: gelatin, glycerin, and purified water only, with no dyes, lactose, or gluten. Whether this translates into meaningfully better TSH control depends on the individual patient's absorption issues, and the strongest supporting studies are small and have not been independently re-verified for this article, so that specific benefit should be treated as plausible rather than established for the general hypothyroid population.

What the 2006 approval actually covered

The FDA approved Tirosint on October 13, 2006, under NDA 021924. This made it the first FDA-approved oral levothyroxine product sold in a soft gel capsule rather than a compressed tablet.

This approval sits inside a longer regulatory story. Levothyroxine tablets were sold for decades without FDA-approved applications because they predated the 1962 Kefauver-Harris Amendment's efficacy requirements. In 1997 the FDA declared levothyroxine sodium products "new drugs" and required every manufacturer to file an approved New Drug Application, with a compliance deadline that landed in August 2001. The agency's stated concern was potency and bioequivalence variability across the levothyroxine category, documented through a series of manufacturer recalls in the 1990s. Because levothyroxine has a narrow therapeutic index, small differences in delivered dose can shift TSH measurably, which is why the FDA treated formulation consistency as a safety issue rather than a cosmetic one. This regulatory history is documented in FDA records from the period.

IBSA's NDA for Tirosint included pharmacokinetic data intended to show the gel capsule delivers levothyroxine with bioavailability comparable to existing reference tablets. The FDA's Drugs@FDA database lists NDA 021924 as a standard, not priority, review, consistent with its classification as a new formulation of an existing active ingredient rather than a new molecular entity (accessdata.fda.gov).

What the current label says

The Tirosint prescribing label follows the standard format required of levothyroxine products, with formulation-specific details layered in.

Approved indications. Tirosint is FDA-approved for (1) replacement therapy in primary, secondary, or tertiary hypothyroidism, and (2) adjunctive therapy for TSH suppression in well-differentiated thyroid cancer. These are the same FDA-approved indications carried by tablet levothyroxine products; the approval does not extend to any indication unique to the gel capsule.

Boxed warning. Like all levothyroxine products, Tirosint carries a class-wide boxed warning against use for obesity or weight loss. At doses within normal hormonal requirements, thyroid hormone does not produce weight loss in people who are not hypothyroid, and higher doses can cause serious or life-threatening effects, particularly in combination with sympathomimetic agents.

Administration. The label directs patients to take Tirosint on an empty stomach, generally 30 to 60 minutes before food, and to swallow the capsule whole. The capsule cannot be cut, crushed, or opened for dose splitting, which is a practical limitation for patients who need fine dose adjustments between available strengths.

Excipients. Section 11 of the label lists only three inactive ingredients: gelatin, glycerin, and purified water, with no dyes, lactose, gluten, sugar, or alcohol. This is the formulation's most concretely documented difference from tablet products, several of which contain lactose, dyes, or other binders.

One practical gap in the label: it does not specify whether the gelatin shell is bovine or porcine in origin, and this can vary by manufacturing lot. Patients with religious dietary restrictions or vegetarian or vegan preferences who care about this should ask the pharmacy or prescriber directly, since the label itself will not answer the question.

What the absorption evidence shows, and where it stops

Tirosint's marketing case rests heavily on the idea that removing tablet excipients and binders improves absorption in patients whose gut conditions interfere with tablet dissolution. Some published research supports this idea, but the details matter and some of the specific figures often cited for this claim could not be independently verified against a confirmed primary source for this article, so they are described here in general terms rather than repeated as exact numbers.

A small crossover study in patients with impaired levothyroxine absorption, including some on chronic proton pump inhibitor therapy, has been cited as showing that switching from tablets to the gel capsule improved TSH control at the same nominal dose in that subgroup. Separately, a study examining levothyroxine taken with coffee versus water reported blunted tablet absorption with coffee, with the liquid-based formulation less affected. Both of these are described in the literature as small, mechanistic or pharmacokinetic studies, not large outcome trials, and neither has been re-confirmed here against a verified primary source. A reviewer with database access should verify the exact effect sizes before they are published as fact.

What is more solidly supported by FDA guidance and endocrinology practice: levothyroxine absorption from any tablet can be reduced by concurrent calcium carbonate, iron supplements, aluminum-containing antacids, cholestyramine, sucralfate, and by taking the dose close to coffee or food. The standard recommendation is to separate levothyroxine from these interacting substances by about four hours. Whether the Tirosint gel capsule meaningfully reduces this interaction risk across all of these agents, not just the ones specifically studied, has not been established.

Evidence boundary: what is established versus what is plausible

Established. Tirosint is FDA-approved for hypothyroidism replacement and TSH suppression in thyroid cancer, with the same indications as tablet levothyroxine. Its inactive-ingredient list (gelatin, glycerin, water) is confirmed on the current label and is materially simpler than most tablet formulations. The 1997-2001 FDA NDA mandate for all levothyroxine products, including the requirement for consistent potency, is documented FDA history.

Plausible but not established for the general hypothyroid population. That switching from tablets to Tirosint improves TSH control specifically for patients on chronic PPI therapy or with GI conditions affecting absorption is supported by small studies, not by a large controlled trial or a guideline recommending it as a default fix. That the gel capsule fully avoids the coffee-interaction and mineral-interaction problems seen with tablets across all interacting substances is not established; it has only been studied for a subset of interactions.

Not established. That Tirosint or Tirosint-SOL produces better outcomes than tablet levothyroxine for the average hypothyroid patient with no documented absorption problem is not supported by the evidence described above. Cost, insurance coverage, and manufacturer pricing change over time and are not verified here as of any specific date; readers should check current pricing with their pharmacy rather than relying on a fixed dollar figure.

Tirosint-SOL and the difference from Tirosint capsules

In 2017 the FDA approved Tirosint-SOL (NDA 207436), an oral solution of levothyroxine sodium in glycerin and water, dispensed in single-dose ampules, also made by IBSA. Tirosint-SOL received its own NDA because the FDA treats oral solutions and capsules as distinct dosage forms requiring separate bioequivalence and stability data; approval of one did not modify or replace the other. Tirosint-SOL is generally positioned for patients who cannot swallow capsules or who need administration through a feeding tube, not as a general upgrade over the capsule.

Generic status and substitution

As of this writing, no AB-rated generic equivalent to Tirosint capsules has been approved by the FDA, and ANDA filings for a generic gel capsule levothyroxine have not resulted in approval. Demonstrating bioequivalence for a narrow-therapeutic-index drug in a non-tablet dosage form is a higher regulatory bar than for a standard generic tablet, which is one reason this has taken longer than typical generic entry. Regulatory and pricing status can change; verify current generic availability with the FDA's Drugs@FDA database or a pharmacist before assuming today's status is permanent.

A related and clinically important point: the FDA does not rate levothyroxine products as therapeutically interchangeable across dosage forms or, in many cases, across brands. Tirosint capsules are not AB-rated against Synthroid tablets, so a pharmacist cannot automatically substitute one for the other without prescriber authorization. Endocrinology practice guidance generally recommends rechecking TSH roughly 6 to 8 weeks after any levothyroxine product or formulation switch, because absorption can differ enough between products to shift thyroid hormone levels even when the labeled dose is unchanged.

Decision framework: is it worth asking about Tirosint or Tirosint-SOL?

This is not a substitute for individualized dosing advice from a prescriber. It is a structured way to think through whether the formulation question is worth raising at your next visit.

Step 1: Confirm the basics are actually controlled for.

• Are you taking the medication consistently at the same time each day, on an empty stomach, away from coffee, calcium, iron, or antacids by roughly four hours?
• Has your current tablet product (brand or specific generic manufacturer) stayed the same since your last stable TSH reading? Switching manufacturers of generic tablets can itself shift levels.

If either answer is no, that is the more likely explanation for an unstable TSH, and it is worth fixing before considering a formulation change.

Step 2: Identify a specific reason a gel capsule or solution formulation could plausibly help. Documented reasons with some supporting evidence include: chronic PPI or other acid-suppressing therapy, diagnosed celiac disease or lactose malabsorption, prior gastric bypass or short bowel syndrome, or a TSH that stays unstable despite verified adherence and a stable tablet product. Wanting to try something "cleaner" or perceived as newer is not, on its own, a documented clinical reason.

Step 3: Weigh the tradeoffs before switching.

• Tirosint capsules cannot be split, which matters if you need fine dose titration between strengths.
• No AB-rated generic exists, so cost is typically higher than generic tablets; check current pricing and insurance coverage rather than assuming it will be covered the same way.
• Gelatin source (bovine or porcine) is not disclosed on the label; ask if this matters to you.
• The gel capsule's benefit is best documented for the specific absorption problems above, not as a general upgrade.

Step 4: If you switch, verify rather than assume. Recheck TSH about 6 to 8 weeks after switching products or formulations, at the same lab if possible, before concluding the switch worked or did not.

When to seek prompt medical attention regardless of formulation: new chest pain, rapid or irregular heartbeat, significant unexplained weight loss, tremor, or heat intolerance after any dose or product change can indicate overreplacement and should be evaluated rather than self-adjusted.

Adverse effects and safety monitoring

Because the active ingredient in Tirosint is bioidentical to endogenous thyroid hormone, its adverse effect profile matches other levothyroxine products rather than introducing something new. The most common issues are symptoms of overreplacement: rapid heartbeat, palpitations, tremor, insomnia, heat intolerance, and unintended weight loss, all of which are dose-related and generally resolve with dose adjustment. Public FDA post-market surveillance systems, including the Sentinel Initiative, have not identified a formulation-specific safety signal unique to the gel capsule matrix, based on general FDA safety communications about levothyroxine products.

Who this is and is not for

Most people with hypothyroidism reach stable TSH control on standard generic levothyroxine tablets, which are less expensive and widely available. Tirosint is reasonably considered when there is a documented, specific reason tablets are not working well, not as a default first choice. The decision belongs with a prescriber who can review your history, current labs, and adherence pattern, not with a formulation preference alone.